ProShares Short S&P500 (SH)
ProShares Short S&P500: Resist The Temptation
The ProShares Short S&P500 (SH) is highlighted as an unattractive vehicle for betting against the S&P 500. Short-term market shocks, like crude oil's March spike, may tempt investors to use SH, but such moves are rarely profitable long-term. Profits from SH are more likely due to luck than skill and tend to reverse to losses over time.
ProShares Short S&P 500 $SH Shares Sold by B. Riley Wealth Advisors Inc.
B. Riley Wealth Advisors Inc. decreased its position in shares of ProShares Short S&P 500 (NYSEARCA:SH) by 16.9% during the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 77,345 shares of the real estate investment trust's
ORG Partners LLC Sells 24,209 Shares of ProShares Short S&P 500 $SH
ORG Partners LLC trimmed its holdings in ProShares Short S&P 500 (NYSEARCA:SH) by 85.5% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,101 shares of the real estate investment trust's stock after selling 24,209 shares during the period. ORG
47,211 Shares in ProShares Short S&P 500 $SH Bought by Abbington Investment Group
Abbington Investment Group bought a new position in ProShares Short S&P 500 (NYSEARCA:SH) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 47,211 shares of the real estate investment trust's stock, valued at approximately $1,745,000. ProShares Short S&P 500 accounts for
SH: Seasonality Points Towards A Tactical Trade
The ProShares Short S&P500 ETF (SH) is an inverse fund, producing -1x of the daily performance of the S&P 500. Seasonal weakness in the S&P 500, especially in September/October and post-election years, can create tactical opportunities for SH. Successful SH trading requires clear entry and exit points; holding without a plan can result in losses.
IDMC Provides Positive Recommendation for Bio-Thera Solution's BAT4406F (ADCC-Enhanced Anti-CD20 mAb) in Neuromyelitis Optica Spectrum Disorder Based on Interim Analysis of Pivotal Phase II/III Trial
GUANGZHOU, China , July 2, 2025 /PRNewswire/ -- Bio-Thera Solutions, Inc. (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, today announced that the Independent Data Monitoring Committee (IDMC) has recommended early study termination for the pivotal Phase II/III trial of BAT4406F in neuromyelitis optica spectrum disorder (NMOSD) based on positive interim analysis results. Following this recommendation, Bio-Thera has decided to close patient enrollment ahead of schedule.
SH Can Provide Investors Inverse Risk To The Market
SH offers a 1x inverse daily performance of the S&P 500, making it suitable for hedging against short-term market volatility. SH is less prone to value decay than heavily leveraged inverse ETFs, allowing for longer holding periods, but is not ideal for long-term bearish bets. Geopolitical risks and upcoming trade policy deadlines could trigger market volatility, presenting tactical opportunities to use SH.
Bio-Thera Solutions and Hikma Pharmaceuticals announce FDA approval of STARJEMZA® (ustekinumab-hmny) Injection, a biosimilar referencing STELARA® (ustekinumab) Injection
GUANGZHOU, China and LONDON , May 27, 2025 /PRNewswire/ -- Bio-Thera Solutions, Ltd (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of biosimilars and innovative assets and Hikma Pharmaceuticals PLC, along with its wholly owned subsidiary Hikma Pharmaceuticals USA Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved STARJEMZA® (ustekinumab-hmny) Injection, a biosimilar referencing Stelara® (ustekinumab) Injection. STARJEMZA® is Bio-Thera's third FDA approved product.
Bio-Thera Solutions and Hikma Pharmaceuticals Announce FDA Approval of STARJEMZA® (ustekinumab-hmny) Injection, a biosimilar referencing STELARA® (ustekinumab) Injection
GUANGZHOU, China and LONDON , May 27, 2025 /PRNewswire/ -- Bio-Thera Solutions, Ltd (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of biosimilars and innovative assets and Hikma Pharmaceuticals PLC, along with its wholly owned subsidiary Hikma Pharmaceuticals USA Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved STARJEMZA® (ustekinumab-hmny) Injection, a biosimilar referencing Stelara® (ustekinumab) Injection. STARJEMZA® is Bio-Thera's third FDA approved product.
Can S&P 500 Bounce Back in Q2? ETFs in Focus
As economic concerns and trade tensions mount, strategists are lowering their outlooks for the S&P 500. A Q2 rebound is less likely for the index.
Trump's Tariffs Shake Markets: ETFs to Watch
President Trump's tariffs unleash a fresh wave of chaos in global markets. Investors should keep an eye on these ETFs.
Here's Why S&P 500 ETFs Are Soaring: Trump, Earnings & Economy
The S&P 500 has hit a new all-time high thanks to deregulation hopes in the Trump era, a resilient economy, easing inflation and an upbeat start to the earnings season.
SH: Best Direct Hedge Idea Against S&P 500 Bear Market In 2025?
ProShares Short S&P 500 can be used as a hedge against market downturns, working exceptionally well with high interest income on cash holdings boosting its performance. In the face of a strong market uptrend, SH's -21% total return since September 2023 outperformed expectations, highlighting its effectiveness as a hedging tool. Owning SH in limited quantities reduces net stock market exposure, while offering some protection against a possible 2025 bear market or crash on Wall Street.
SH: An Effective Market Hedge With Hidden Income
The ProShares Short S&P500 ETF offers a relatively high income hedge against a decline in the S&P500. The SH ETF has historically tracked the inverse of the S&P500 effectively, minus the 0.88% expense fee, and has seen renewed inflows recently. The SH ETF is aimed at benefitting from short-term declines in the S&P500 but has performed well historically over extended periods following high-yield spreads between cash and stocks.
SH: Arguably The Best Way To Short The S&P 500
SH is a simple way to short the S&P 500, consistently outperforming its intended -1x target and offering an impressive 6.11% TTM dividend. It outperforms when the VIX is low and the S&P 500 makes large daily swings. This was evident on Wednesday when the S&P 500 closed +0.85% higher, while SH closed only -0.77% lower. The cumulative effect of this can be very beneficial.
SH: A Simple, Effective Bet Against The S&P 500
ProShares Short S&P500 ETF is an unleveraged and easy way to short the S&P 500. SH does not always achieve its intended -1x daily performance of the S&P 500, but this tends to work in its favor while volatility is low. SH pays a quarterly dividend from its holdings in T-Bills.
SH: Don't Short The S&P 500, At Least Not Yet
The S&P 500 is expected to consolidate at 4,800 before breaking out and making new highs. Buying activity in SH is still too high and suggests caution on shorting the S&P 500 at current levels. Assets under management in SH are contracting but are still high enough to suggest the stock market has higher to go.
SH: There Are Better Ways To Bet Against Stocks
Shorting and inverse trading does not work well in the long run, despite disagreement among investors. ProShares Short S&P500 ETF offers inverse exposure to the daily performance of the S&P 500. SH achieves its net short position through swap contracts and is subject to risks associated with derivatives.
7 Inverse ETFs for the Opportunistic Bear
From glancing at the headlines, the concept of acquiring inverse ETFs – that is, exchange-traded funds that rise in value as their underlying securities, assets or sectors fall – doesn't seem very relevant. After all, the September jobs report came in hotter than expected.
SH: Mr. Market Is Paying More To Be Short S&P 500, Than Long
ProShares Short S&P500 is currently paying a higher cash yield than owning stocks long through a regular index fund. The trust is yielding around 3.5% annualized on a forward basis, with excess cash income beyond its management fee paid to holders. This setup is encouraging risk takers to go short stocks instead of long, a major change of tune for investors.